1. MamisTrist
2. STOCKnLAW
3. lorenz05
1.MamisTrist 12/24/2017
Waiting for Savolitinib PIII/ FDA Breakthrough Therapy
2.MamisTrist 07/23/2018
Company has initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine tumors …
3.STOCKnLAW 12/24/2017
Long
4.STOCKnLAW 03/12/2018
Reports FY EPS loss of $0.43 and revenue of $241.2M (+11.6% Y/Y)
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW